{"entity":{"id":"nct04008797","kind":"trial","name":"A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor","aka":[],"tldr":"A phase 1/2 trial of Lenvatinib and Doxorubicin in endometrial cancer, hepatocellular carcinoma and colorectal cancer, run by Eisai Inc., active and no longer recruiting.","summary":"A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor is a phase 1/2 interventional study registered as NCT04008797 by Eisai Inc., with 301 participants enrolled, started 2019-07-11 and due to reach its primary completion in 2027-03-31. Interventions recorded: E7386, Lenvatinib, Doxorubicin and Paclitaxel.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04008797","url":"https://clinicaltrials.gov/study/NCT04008797"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["endometrial","hcc","colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":["lenvatinib","doxorubicin"],"companies":["eisai"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04008797","phase":"1/2","setting":"An Open-label Study of E7386 in Combination With Other Anticancer Drug(s) in Subjects With Solid Tumors","sponsor":"Eisai Inc.","enrolled":301,"outcomes":[]},"route":"/trials/nct04008797/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}],"drug":[{"id":"doxorubicin","kind":"drug","name":"Doxorubicin","route":"/drugs/doxorubicin/"},{"id":"lenvatinib","kind":"drug","name":"Lenvatinib","route":"/drugs/lenvatinib/"}],"company":[{"id":"eisai","kind":"company","name":"Eisai","route":"/companies/eisai/"}]}}